Novoron is developing pharmaceutical therapies that target low-density lipoprotein receptors to enhance nerve regeneration in the central nervous system. Their approach aims to improve outcomes for conditions such as Alzheimer's disease, multiple sclerosis, and spinal cord injuries by restoring the brain's and spinal cord's natural regenerative capabilities.
Funding
$9.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Central nervous system (CNS) disorders like Alzheimer's disease, multiple sclerosis, and spinal cord injuries result in neurodegenerative failure, hindering the brain and spinal cord's natural ability to regenerate damaged tissues. Current treatments often fail to restore full functionality due to the limited regenerative capacity of the CNS. This unmet need leaves patients with significant long-term disabilities and reduced quality of life.
Solution
Novoron is developing first-in-class pharmaceutical therapies that target low-density lipoprotein receptor protein 1 (LRP1) to enhance nerve regeneration and remyelination within the CNS. Their technology enables precise targeting of LRP1 at both whole-receptor and micro-domain levels, restoring the body’s natural ability to regenerate tissues of the brain and spinal cord after damage or disease. By targeting LRP1, Novoron's approach aims to reduce the spread of tau, increase remyelination, and promote functional motor recovery. This approach offers potential treatments for Alzheimer's disease and other tauopathies, multiple sclerosis, and spinal cord injuries.
Target Audience
The primary target audience includes individuals suffering from neurological damage and diseases in the CNS, such as Alzheimer’s disease, multiple sclerosis, and spinal cord injuries.
Features
- LRP1-targeting molecules designed to reduce tau spread in tauopathies like Alzheimer's disease and CTE.
- Therapies demonstrating significant functional motor recovery in animal models of spinal cord injury.
- Approach shown to increase remyelination, potentially reducing disease severity and improving long-term prognosis in multiple sclerosis.
- Technology enables precise targeting of LRP1 at both whole-receptor and micro-domain levels.